315 related articles for article (PubMed ID: 29345636)
1. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.
Obermajer N; Urban J; Wieckowski E; Muthuswamy R; Ravindranathan R; Bartlett DL; Kalinski P
Nat Protoc; 2018 Feb; 13(2):335-357. PubMed ID: 29345636
[TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues.
Kokolus KM; Obermajer N; Kalinski P
Methods Enzymol; 2020; 635():149-166. PubMed ID: 32122543
[TBL] [Abstract][Full Text] [Related]
3. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs.
Miki K; Nagaoka K; Harada M; Hayashi T; Jinguji H; Kato Y; Maekawa R
Int Immunopharmacol; 2014 Dec; 23(2):499-504. PubMed ID: 25284343
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
[TBL] [Abstract][Full Text] [Related]
7. Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.
Kumbhari A; Egelston CA; Lee PP; Kim PS
Front Immunol; 2020; 11():584680. PubMed ID: 33193401
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
9. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
10. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
11. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
[TBL] [Abstract][Full Text] [Related]
12. Lymph Node Delivery Strategy Enables the Activation of Cytotoxic T Lymphocytes and Natural Killer Cells to Augment Cancer Immunotherapy.
Jiang D; Gao T; Liang S; Mu W; Fu S; Liu Y; Yang R; Zhang Z; Liu Y; Zhang N
ACS Appl Mater Interfaces; 2021 May; 13(19):22213-22224. PubMed ID: 33955746
[TBL] [Abstract][Full Text] [Related]
13. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen.
Ozawa Y; Suda T; Nagata T; Hashimoto D; Nakamura Y; Enomoto N; Inui N; Koide Y; Nakamura H; Chida K
Am J Respir Cell Mol Biol; 2009 Oct; 41(4):440-8. PubMed ID: 19202004
[TBL] [Abstract][Full Text] [Related]
17. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
[TBL] [Abstract][Full Text] [Related]
18. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
19. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.
Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH
Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090
[TBL] [Abstract][Full Text] [Related]
20. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
